ACRS

Aclaris Therapeutics, Inc.

Fundamental data last updated:May 15, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Diagnostics & Research

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/06/2026

Business Summary

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

 


Analyze ACRS on TradingView

VALUATION

P/E

-9.41

Market Cap ($M USD)

$613.83M

Forward P/E

-7.45

PEG

0.28

PRICE TO SALES

73.36

PRICE TO BOOK

4.56

EV / EBITDA

-8.03

5-Year Average P/E

Free Cash Flow Yield

-8.52%

DCF Value

$-0.96

Graham Number

N/A

Price to FCF

-11.74

EV to FCF

-11.23

Earnings Yield

-10.62%

FCF Yield

-8.52%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.54

Next Year EPS Growth Estimate

-$0.68

Next Year Revenue Growth Estimate

$11.44B

Return on Equity (ROE)

-55.89%

FREE CASH FLOW

Operating Margin

-961.91%

Debt-to-Equity

0.02

Piotroski F-Score

2

Altman Z-Score

-0.95

Return on Invested Capital (ROIC)

-46.97%

Current Ratio

4.03

Quick Ratio

4.03

Net Debt to EBITDA

0.36

Interest Coverage

0.00

Gross Profit margin

76.34%

FCF PER SHARE

$-0.41

REVENUE PER SHARE

$0.06

Analyze ACRS on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be pricing Aclaris Therapeutics, Inc. with a heavy dose of skepticism. With a Forward P/E of -7.04 and an Altman Z-score of -1.16, the financial health is precarious, suggesting significant risk of distress. The negative Earnings Yield further underscores the absence of profitability. Recent pricing indicated it traded well below its DCF Value, hinting at potential mispricing. However, the lack of a Graham Number adds to the uncertainty surrounding its intrinsic value.

AI Exposure / Tech Reliance

Operating in the Medical - Diagnostics & Research industry, Aclaris Therapeutics is well-positioned to leverage AI advancements for drug discovery and diagnostics. The healthcare sector's ongoing digital transformation could provide opportunities for innovation and efficiency. However, the company's ability to capitalize on these shifts remains to be proven.

The Bull Case

For the bold investor, Aclaris presents a tantalizing opportunity. Despite a Piotroski F-Score of 2, its low Debt/Equity ratio of 0.02 suggests financial prudence. The impressive Sales Growth forecast of over 11 billion percent next year hints at explosive potential. With a Current Ratio of 4.03, the company maintains strong liquidity, offering a cushion against operational hiccups.

The Bear Case

Yet, the structural risks are glaring. A Price/Sales ratio of 71.06 and a Price/Book of 4.42 signal overvaluation. The Operating Margin of -961.91% and ROIC of -46.97% paint a grim picture of operational inefficiency. Trading close to its 52-week high, the stock appears technically overextended, raising caution flags for potential investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$10.60

Institutional Ownership %

1-Year Beta

0.78

Insider Buying % (6 Mo)

Distance to 52-Week High

0.59%

Distance to 52-Week Low

77.21%

EARNINGS SURPRISE %

6.25%

50-DAY SMA

$4.01

200-DAY SMA

$2.90

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.